---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-251712"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:38:15.924468+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UroGen Q3 revenue $25.2M, net loss $23.7M; UGN-102 PDUFA June 2025; cuts FY revenue view

## Summary
- JELMYTO Q3 net product revenue $25.2M (+21% YoY from $20.9M).
- Net loss $23.7M ($0.55/share) vs $21.9M ($0.68/share) in Q3 2023.
- NDA for UGN-102 accepted; PDUFA target action date June 13, 2025.
- Full-year 2024 JELMYTO revenue expected below prior guidance low end; still low double-digit YoY growth.
- Cash, equivalents, marketable securities $254.2M as of Sept 30, 2024.

## SEC filing metadata
- accession: 0001193125-24-251712
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524251712/0001193125-24-251712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524251712/d910412d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-251712
- JSON: https://secwatch.observer/filing/0001193125-24-251712.json
- Plain text: https://secwatch.observer/filing/0001193125-24-251712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.